Literature DB >> 19450761

Validation of the hematopoietic cell transplantation-specific comorbidity index (HCT-CI) in single and multiple institutions: limitations and inferences.

Mohamed L Sorror, Barry Storer, Rainer F Storb.   

Abstract

Entities:  

Mesh：

Year:  2009        PMID： 19450761      PMCID： PMC2684868          DOI： 10.1016/j.bbmt.2009.02.007

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN： 1083-8791            Impact factor:   5.742


× No keyword cloud information.
  12 in total

1.  Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences.

Authors:  Mohamed L Sorror; Sergio Giralt; Brenda M Sandmaier; Marcos De Lima; Munir Shahjahan; David G Maloney; H Joachim Deeg; Frederick R Appelbaum; Barry Storer; Rainer Storb
Journal:  Blood       Date:  2007-09-14       Impact factor: 22.113

2.  [Usefulness of hematopoietic cell transplantation-specific comorbidity index after allogeneic hematopoietic stem cell transplantation].

Authors:  Katsumichi Fujimaki; Rika Sakai; Shin Fujisawa; Hiroyuki Fujita; Masatsugu Tanaka; Maki Hagihara; Hideyuki Koharazawa; Takuya Miyazaki; Naoto Tomita; Heiwa Kanamori; Atsuo Maruta; Yoshiaki Ishigatsubo
Journal:  Gan To Kagaku Ryoho       Date:  2008-01

3.  Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT.

Authors:  Mohamed L Sorror; Michael B Maris; Rainer Storb; Frederic Baron; Brenda M Sandmaier; David G Maloney; Barry Storer
Journal:  Blood       Date:  2005-06-30       Impact factor: 22.113

4.  Outcomes of alemtuzumab-based reduced intensity conditioning stem cell transplantation using unrelated donors for myelodysplastic syndromes.

Authors:  Zi Yi Lim; Aloysius Y L Ho; Wendy Ingram; Michelle Kenyon; Laurence Pearce; Barbara Czepulkowski; Stephen Devereux; Rafael F Duarte; Antonio Pagliuca; Ghulam J Mufti
Journal:  Br J Haematol       Date:  2006-08-25       Impact factor: 6.998

5.  The importance of classifying initial co-morbidity in evaluating the outcome of diabetes mellitus.

Authors:  M H Kaplan; A R Feinstein
Journal:  J Chronic Dis       Date:  1974-09

6.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

Authors:  M E Charlson; P Pompei; K L Ales; C R MacKenzie
Journal:  J Chronic Dis       Date:  1987

7.  Comparable antileukemia/lymphoma effects in nonremission patients undergoing allogeneic hematopoietic cell transplantation with a conventional cytoreductive or reduced-intensity regimen.

Authors:  Dai Maruyama; Takahiro Fukuda; Ruri Kato; Satoshi Yamasaki; Eiji Usui; Yuriko Morita-Hoshi; Sung-Won Kim; Shin-ichiro Mori; Yuji Heike; Atsushi Makimoto; Kinuko Tajima; Ryuji Tanosaki; Kensei Tobinai; Yoichi Takaue
Journal:  Biol Blood Marrow Transplant       Date:  2007-05-29       Impact factor: 5.742

8.  Comorbidity predicts survival in myelodysplastic syndromes or secondary acute myeloid leukaemia after allogeneic stem cell transplantation.

Authors:  A Boehm; W R Sperr; G Leitner; N Worel; L Oehler; E Jaeger; M Mitterbauer; O A Haas; P Valent; P Kalhs; W Rabitsch
Journal:  Eur J Clin Invest       Date:  2008-12       Impact factor: 4.686

9.  The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation.

Authors:  L Farina; B Bruno; F Patriarca; F Spina; R Sorasio; M Morelli; R Fanin; M Boccadoro; P Corradini
Journal:  Leukemia       Date:  2009-02-05       Impact factor: 11.528

10.  Prognostic importance of comorbidity in a hospital-based cancer registry.

Authors:  Jay F Piccirillo; Ryan M Tierney; Irene Costas; Lori Grove; Edward L Spitznagel
Journal:  JAMA       Date:  2004-05-26       Impact factor: 56.272
View more
  11 in total

1.  Analysis of non-HLA genomic risk factors in HLA-matched unrelated donor hematopoietic cell transplantation for chronic myeloid leukemia.

Authors:  Kim F Pearce; Stephanie J Lee; Michael Haagenson; Effie W Petersdorf; Jean Norden; Matthew P Collin; John P Klein; Stephen R Spellman; Shelagh A Lowerson; Stella Davies; Anne M Dickinson
Journal:  Haematologica       Date:  2012-01-22       Impact factor: 9.941

2.  Acute graft-versus-host disease: more than just alloreactivity.

Authors:  Richard Champlin
Journal:  Blood       Date:  2014-07-10       Impact factor: 22.113

Review 3.  Reduced intensity conditioning allogeneic hematopoietic cell transplantation for adult acute myeloid leukemia in complete remission - a review from the Acute Leukemia Working Party of the EBMT.

Authors:  Salyka Sengsayadeth; Bipin N Savani; Didier Blaise; Florent Malard; Arnon Nagler; Mohamad Mohty
Journal:  Haematologica       Date:  2015-07       Impact factor: 9.941

4.  Allogeneic transplantation as post-remission therapy for cytogenetically high-risk acute myeloid leukemia: landmark analysis from a single prospective multicenter trial.

Authors:  Matthias Stelljes; Dietrich W Beelen; Jan Braess; Maria C Sauerland; Achim Heinecke; Björna Berning; Hans J Kolb; Ernst Holler; Rainer Schwerdtfeger; Renate Arnold; Karsten Spiekermann; Carsten Müller-Tidow; Hubert L Serve; Gerda Silling; Wolfgang Hiddemann; Wolfgang E Berdel; Thomas Büchner; Joachim Kienast
Journal:  Haematologica       Date:  2011-04-01       Impact factor: 9.941

5.  Clinical comorbidity predictive measures in ex vivo T-cell-depleted allogeneic hematopoietic stem cell transplantation.

Authors:  R Q Le; X Tian; N A Jain; K Lu; S Ito; D A Draper; P Anandi; C S Hourigan; N Dunavin; A John Barrett; M Battiwalla
Journal:  Bone Marrow Transplant       Date:  2015-05-18       Impact factor: 5.483

6.  Impact of genomic risk factors on outcome after hematopoietic stem cell transplantation for patients with chronic myeloid leukemia.

Authors:  Anne M Dickinson; Kim F Pearce; Jean Norden; Stephen G O'Brien; Ernst Holler; Heike Bickeböller; Yesilda Balavarca; Vanderson Rocha; Hans-Jochem Kolb; Ilona Hromadnikova; Petr Sedlacek; Dietger Niederwieser; Ronald Brand; Tapani Ruutu; Jane Apperley; Richard Szydlo; Els Goulmy; Wolfgang Siegert; Theo de Witte; Alois Gratwohl
Journal:  Haematologica       Date:  2010-03-19       Impact factor: 9.941

7.  Assessing the Prognosis of Patients with Myelodysplastic Syndromes (MDS).

Authors:  Annika Kasprzak; Kathrin Nachtkamp; Norbert Gattermann; Ulrich Germing
Journal:  Cancers (Basel)       Date:  2022-04-12       Impact factor: 6.575

Review 8.  The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach.

Authors:  Jan J Cornelissen; Alois Gratwohl; Richard F Schlenk; Jorge Sierra; Martin Bornhäuser; Gunnar Juliusson; Zdenek Råcil; Jacob M Rowe; Nigel Russell; Mohamad Mohty; Bob Löwenberg; Gerard Socié; Dietger Niederwieser; Gert J Ossenkoppele
Journal:  Nat Rev Clin Oncol       Date:  2012-09-04       Impact factor: 66.675

9.  Post-transplant multimorbidity index and quality of life in patients with chronic graft-versus-host disease-results from a joint evaluation of a prospective German multicenter validation trial and a cohort from the National Institutes of Health.

Authors:  Daniel Wolff; Philipp Y Herzberg; Anne Herrmann; Steven Z Pavletic; Pia Heussner; Friederike Mumm; Christina Höfer; Inken Hilgendorf; Philipp G Hemmati; Ernst Holler; Hildegard Greinix; Sandra A Mitchell
Journal:  Bone Marrow Transplant       Date:  2020-07-31       Impact factor: 5.483

10.  Parental limited English proficiency in pediatric stem cell transplantation: Clinical impact and health care utilization.

Authors:  Joanna M Robles; Jesse D Troy; Kristin M Schroeder; Paul L Martin; Thomas W LeBlanc
Journal:  Pediatr Blood Cancer       Date:  2021-06-09       Impact factor: 3.838
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.